A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-Cell lineage non-Hodgkin lymphoma (B-NHL)
Email this document.
Enter your email address below to send this document.